The National Health Insurance Administration announces that the prices of 5,500 types of drugs will be reduced starting from April 1st, lowering NHI expenditures by NT$8.18 billion a year. Meanwhile, the prices of 8,000 drugs are not adjusted and the prices of 36 drugs are increased.

Because of the impact of the Covid-19 pandemic, the NHI drugs were not reviewed in 2021 and 2022. Also, the affected items are the fewest since 2013, when the Drug Expenditure Target (DET) was implemented.

In order to ensure a steady drug supply, the drugs below the floor price won’t be adjusted, the price will be set at the floor price if the adjustment price below it. The drug confirmed a shortage by TFDA will be not adjusted either.